Ua faailoa mai e le European Medicines Agency (EMA) ua ia tuuina atu le faatagaga tau maketi (CMA) mo le Pfizer's oral coronavirus togafitiga, Paxlovid.

I le lotolotoi o le salalau pea o le siama Omikarona fa'amalosi i totonu Europe, fai mai EMA o le fualaau muamua mo togafitiga o le coronavirus ua fautuaina "mo le togafitia o le COVID-19 i tagata matutua e le manaʻomia se okesene faaopoopo ma o loʻo i ai i le faʻateleina o le lamatiaga o le faʻamaʻi e oʻo i le ogaoga."

O le CMA, o le tala lea a le EMA, e faʻaaogaina e faʻavave ai le faʻatagaina o vailaʻau "i taimi o faʻalavelave faʻafuaseʻi o le soifua maloloina lautele."

Faatasi ai ma le faamaoniga a le pulega a Europa, Paxlovid ua avea ma vailaau antiviral muamua e tuuina atu e le gutu e fautuaina i le EU mo le togafitia ole COVID-19.

Le faamaoniga a Paxlovid mulimuli i le faʻatagaina ia Tesema o le antibody togafitiga Xevudy, gaosia e GlaxoSmithKline ma Vir Biotechnology, faʻapea foʻi ma Kineret e le kamupani Suetena Sobi, lea na muaʻi avea ma vailaʻau faʻamaʻi ae mafai ona "faʻaitiitia" faʻamaʻi pipisi o le COVID.

O le tauva a Paxlovid, Merck's Lagevrio (molnupiravir), o loʻo tumau pea ona iloiloina e le EMA, ona o lona aoga ua faʻamaonia e maualalo ifo nai lo le mea na faʻamoemoeina.

Na maua uma e Paxlovid ma molnupiravir le faamaoniga mai le US Food and Drug Administration ia Tesema o le tausaga talu ai.

OA MEA E AVEA MAI LENEI TUSI:

The approval of Paxlovid follows the authorization in December of antibody treatment Xevudy, produced by GlaxoSmithKline and Vir Biotechnology, as well as Kineret by Swedish company Sobi, which was originally an arthritis drug but is able to “reduce” COVID-related inflammation.
Amid the ongoing spread of the virus’s Omicron strain in Europe, EMA said that the first coronavirus treatment pill has been recommended “for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
Faatasi ai ma le faʻatagaina a le Europa faʻatonutonu, ua avea Paxlovid ma vailaʻau faʻamaʻi muamua na tuʻuina atu e le gutu e fautuaina i le EU mo le togafitia o le COVID-19.